Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

Prospective Evaluation of Patients With Idiopathic Pulmonary Fibrosis Through an IPF Registry

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00212511
• Other study ID #: 10386-02 A
• Status: Withdrawn
• Phase: N/A
• First received: September 13, 2005
• Last updated: April 26, 2017
• Start date: November 2004
• Est. completion date: January 2018

Study information

• Verified date: April 2017
• Source: New York University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to create a database of demographics and samples in idiopathic pulmonary fibrosis.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria

1. Male or Female greater or equal to age 18.

2. Referral by physician with the diagnosis of IPF, or interstitial lung disease (IPF considered likely).

Exclusion Criteria

(a) Unwilling or unable to give written informed consent.

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Interstitial Pneumonias
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Locations

Country	Name	City	State
United States	NYU School of Medicine	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
New York University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine cellular and molecular determinants of IPF	An IPF Registry is being established to assemble sufficient patients with IPF (especially in its earliest stage) for phase I therapeutic protocols. The Registry will incorporate demographic and clinical data for natural history studies; second, research data on physiology, high-resolution CT scan, questionnaires, and blood samples for blood banking to be collected every 6 months for prospective studies on pathophysiology; and third, response to standard therapies will be monitored to determine cellular and molecular relationships to clinical outcome and predictors of survival. This is done in order to better determine cellular and molecular determinants of IPF. This cohort will be large enough to commence a separate phase I protocol with molecular strategies of intervention.	Long-Term